This might make sense but EUA is not a slam dunk. Evidence that protective efficacy really wanes based on limited and variable studies, and virus neutralizing ab levels don’t tell us what’s happening with memory cells. Also there’s the global equity issue apnews.com/article/europe…
So I recognize that a 3rd immunization would really crank up VNA and that’s a good thing for resilience to the variants of concern, but there will other considerations. It will be interesting to see if FDA says yes or will require a full on study for the EUA.
It would also be good to look at whether we could achieve more durable protection using a prime boost approach with our recombinant protein vaccine? In other words 2 doses of Pfizer followed by ours. But so far not much interest from the United States
Finally, it’s important to remember that when a pharma company sends out a press release: it’s not meant for you, or for me, it’s for the shareholders. It’s meant to jack up the stock prices. A mistake in the design of OWS was to not tying federal funds to control of the message
• • •
Missing some Tweet in this thread? You can try to
force a refresh
